Premium
Symptomatic and quality‐of‐life outcomes after treatment for clinically localised prostate cancer: a systematic review
Author(s) -
Whiting Penny F.,
Moore Theresa H.M.,
Jameson Catherine M.,
Davies Philippa,
Rowlands MariAnne,
Burke Margaret,
Bey Rebecca,
Savovic Jelena,
Donovan Jenny L.
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13499
Subject(s) - medicine , prostate cancer , prostatectomy , brachytherapy , cohort , quality of life (healthcare) , medline , radiation therapy , cochrane library , cohort study , systematic review , cancer , intensive care medicine , meta analysis , nursing , political science , law
To conduct a systematic review of the risks of short‐term outcomes after major treatments for clinically localised prostate cancer. MEDLINE , EMBASE and the Cochrane Library were searched from 2004 to January 2013. Study arms that included ≥100 men with localised prostate cancer in receipt of surgery, radiotherapy or active surveillance and reported symptomatic and quality‐of‐life (QoL) data from 6 to 60 months after treatment were eligible. Data were extracted by one reviewer and checked by another. In all, 64 studies (80 treatment cohorts) were included. Most were single treatment cohorts from the USA or Europe. Radiotherapy was the most common treatment (40 cohorts, including 31 brachytherapy cohorts) followed by prostatectomy (39 cohorts), with only one active surveillance cohort. Most frequently measured symptoms were urinary, followed by sexual, and bowel; QoL was assessed in only 17 cohorts. Most studies used validated measures, although poor data reporting and differences between studies meant that it was not possible to pool data. Data on the precise impact of short‐term symptomatic and QoL outcomes after treatment for localised prostate cancer are of insufficient quality for clear guidance to men about the risks to these aspects of their lives. It is important that future studies focus on collecting core outcomes through validated measures and comply with reporting guidelines, so that clear and accurate information can be derived for men considering screening or treatment for prostate cancer.